John Jesitus
John Jesitus is a medical writer based in Westminster, CO.
Psoriasis research: IL-17, comorbidities take center stage
Based on available evidence, dermatologists should at least discuss biologic drugs with patients who have moderate-to-severe psoriasis and cardiovascular comorbidities. Clearing the skin may improve cardiovascular disease, says an expert.
ADHD and AR: Attack AR first
Treating allergic rhinitis (AR) in children with attention-deficit/hyperactivity disorder (ADHD) appears to significantly improve not only AR, but also ADHD symptoms.
Vismodegib study confirms safety, efficacy for BCC
The largest-ever vismodegib study in advanced basal cell carcinoma, the STEVIE study, confirms pivotal study findings in a real-world setting, helping dermatologists to provide a complete palette of skin cancer treatments.
New thoughts, therapies for vitiligo
Promising treatments under investigation for vitiligo include afamelanotide, prostaglandin analogues and JAK inhibitors. But don't overlook established treatments such as phototherapy and steroid mini-pulses, an expert says.
ADHD: Are off-label atypical antipsychotics appropriate?
The amount of off-label uses of atypical antipsychotic drugs (AAPs) prescribed for children with attention-deficit/hyperactivity disorder (ADHD) raises questions about the appropriateness of AAPs for this indication.
Improving accuracy in NMSC diagnosis
The trend toward smaller biopsies may compromise the accuracy of dermatopathologists' diagnoses.
Organizations offer support for alopecia patients
Key resources for patients, families and healthcare providers who deal with alopecia areata include the National Alopecia Areata Foundation, the Children's Alopecia Project and the American Academy of Dermatology.
American alopecia ninja attacks awareness
American alopecia ninja attacks awareness
American Ninja Warrior competitor Kevin Bull is helping to boost awareness about alopecia areata, while researchers are beginning to tap the potential of JAK inhibitors for this indication.
Payers want more data
A pioneering summit between healthcare payers and groups pursuing standardized outcome measures in dermatology has revealed that payers want outcome measures that are published, universally accepted and practical both for clinicians and payers.
Hypoglycemia guidelines: AAP vs PES
The topic of hypoglycemia in neonates and children has generated significant debate of late, with the American Academy of Pediatrics (AAP) and the Pediatric Endocrine Society (PES) having advanced apparently conflicting guidelines. Here's what community pediatricians need to know to avoid overscreening healthy infants and children without discharging babies who may have glucose-regulation problems beyond the first days of life.

Poll

View Results